LAVA Therapeutics to Move Extraordinary General Meeting to Early November 2025

Core Viewpoint - LAVA Therapeutics has decided to cancel the Extraordinary General Meeting (EGM) scheduled for September 30, 2025, to further discuss the terms of its acquisition by XOMA Royalty Corporation, including cash forecasts and shareholder considerations [2][3]. Group 1: Transaction Details - The acquisition by XOMA Royalty is anticipated to close in the fourth quarter of 2025 [1]. - The EGM will be reconvened by early November 2025, with details to be announced later [5]. - Votes already cast for the original EGM will not count, and shareholders must vote again at the reconvened meeting [5]. Group 2: Company Background - LAVA Therapeutics is a biopharmaceutical company focused on developing bispecific gamma delta T cell engagers using its proprietary Gammabody platform [6]. - The company has partnerships with major pharmaceutical firms, including Johnson & Johnson and Pfizer, for its clinical-stage products targeting various cancers [6].